[go: up one dir, main page]

GB9927757D0 - Treatment of autoimmune diseases - Google Patents

Treatment of autoimmune diseases

Info

Publication number
GB9927757D0
GB9927757D0 GBGB9927757.6A GB9927757A GB9927757D0 GB 9927757 D0 GB9927757 D0 GB 9927757D0 GB 9927757 A GB9927757 A GB 9927757A GB 9927757 D0 GB9927757 D0 GB 9927757D0
Authority
GB
United Kingdom
Prior art keywords
treatment
autoimmune diseases
autoimmune
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9927757.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Mathilda and Terence Kennedy Institute of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology, Mathilda and Terence Kennedy Institute of Rheumatology filed Critical Kennedy Institute of Rheumotology
Priority to GBGB9927757.6A priority Critical patent/GB9927757D0/en
Publication of GB9927757D0 publication Critical patent/GB9927757D0/en
Priority to EP00977741A priority patent/EP1146902A1/en
Priority to PCT/GB2000/004511 priority patent/WO2001037870A1/en
Priority to JP2001539484A priority patent/JP2003514873A/en
Priority to AU15376/01A priority patent/AU1537601A/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
GBGB9927757.6A 1999-11-25 1999-11-25 Treatment of autoimmune diseases Ceased GB9927757D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9927757.6A GB9927757D0 (en) 1999-11-25 1999-11-25 Treatment of autoimmune diseases
EP00977741A EP1146902A1 (en) 1999-11-25 2000-11-27 Treatment of autommune diseases by an agonistic cd40-binding protein
PCT/GB2000/004511 WO2001037870A1 (en) 1999-11-25 2000-11-27 Treatment of autoimmune diseases by an agonistic cd40-binding protein
JP2001539484A JP2003514873A (en) 1999-11-25 2000-11-27 Treatment of autoimmune diseases with active CD40 binding proteins
AU15376/01A AU1537601A (en) 1999-11-25 2000-11-27 Treatment of autoimmune diseases by an agonistic CD40-binding protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9927757.6A GB9927757D0 (en) 1999-11-25 1999-11-25 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
GB9927757D0 true GB9927757D0 (en) 2000-01-26

Family

ID=10865044

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9927757.6A Ceased GB9927757D0 (en) 1999-11-25 1999-11-25 Treatment of autoimmune diseases

Country Status (5)

Country Link
EP (1) EP1146902A1 (en)
JP (1) JP2003514873A (en)
AU (1) AU1537601A (en)
GB (1) GB9927757D0 (en)
WO (1) WO2001037870A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414483A1 (en) * 2001-07-31 2004-05-06 Serono Genetics Institute S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
AU2002346581A1 (en) * 2001-11-26 2003-06-10 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
AU2003230765A1 (en) * 2002-03-29 2003-10-13 Bayhill Therapeutics, Inc. Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
US20070041971A1 (en) * 2003-07-07 2007-02-22 Wagner David H Methods for predicting development of auto-immune diseases and treatment of same
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
CA3148890A1 (en) * 2019-09-11 2021-03-18 Novartis Ag A method for preventing human virus associated disorders in patients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661360B2 (en) * 1991-10-25 1995-07-20 Immunex Corporation Novel cytokine
CZ244399A3 (en) * 1997-01-10 1999-10-13 Biogen, Inc. The use of an anti-CD40L compound for the manufacture of a medicament for the treatment of immunological diseases

Also Published As

Publication number Publication date
WO2001037870A1 (en) 2001-05-31
EP1146902A1 (en) 2001-10-24
AU1537601A (en) 2001-06-04
JP2003514873A (en) 2003-04-22

Similar Documents

Publication Publication Date Title
IL144981A0 (en) Treatment of autoimmune disease
HUP0200079A3 (en) Treatment of infertility
AU7434101A (en) Treatment of bone diseases
HUP0200157A3 (en) Treatment of infertility
HUP0104963A3 (en) Compositions for the treatment of skin diseases
PL336760A1 (en) Treatment of skin diseases
AU3896900A (en) Treatment of pain
GB9927757D0 (en) Treatment of autoimmune diseases
PL336579A1 (en) Treatment of diseases associated with cytokinins
NZ513686A (en) Treatment of trauma
GB2360453B (en) Treatment of skin conditions
IL149281A0 (en) Treatment of cancer
EP1107778A4 (en) Treatment of disease states
AU1405001A (en) Treatment of diseases
GB9908059D0 (en) Diagnosis and treatment of diseases
ZA991783B (en) Therapeutic treatment for autoimmune diseases.
AU1324002A (en) Treatment of demyelinating diseases
GB9919565D0 (en) Treatment of disease
PL351081A1 (en) Treatment of hiatial hernia
EP1165060A4 (en) Treatment of gallstones
GB9710054D0 (en) Treatment of diseases
GB9901310D0 (en) Methods of treatment
GB9917181D0 (en) Methods of treatment
IL143568A0 (en) Treatment of infertility
PL350221A1 (en) Treatment of infertility

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)